Metraipolis › archive › dc_1d133bb95c17

IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS — Europe PMC PMID:34415964

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34415964
DOI
10.1371/journal.pone.0256396
License (as archived)
CC0-1.0
Archived
2026-11-03T06:16:06.397Z
SHA-256 of the archived text
c258a7941f5c1d5317711be4a187b469ed23a1c2bf3ed37b8f5526e26882a79d
Stable URL of this page
https://metraipolis.com/documento/dc_1d133bb95c17

How to cite

IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS — Europe PMC PMID:34415964 — Europe PMC (en), https://europepmc.org/article/MED/34415964 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_1d133bb95c17 (Metraipolis archive dc_1d133bb95c17, sha256 c258a7941f5c1d5317711be4a187b469ed23a1c2bf3ed37b8f5526e26882a79d)
BibTeX
@misc{dc1d133bb95c17,
  title = {IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS — Europe PMC PMID:34415964},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34415964},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_1d133bb95c17; sha256 c258a7941f5c1d5317711be4a187b469ed23a1c2bf3ed37b8f5526e26882a79d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34415964. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Immunization with radiation-attenuated sporozoites (RAS) by mosquito bites provides >90% sterile protection against Plasmodium falciparum malaria in humans. We conducted a clinical trial based on data from previous RAS clinical trials that suggested that 800-1200 infected bites should induce ~50% protective vaccine efficacy (VE) against controlled human malaria infection (CHMI) administered three weeks after the final immunization. Two cohorts were immunized separately. VE was 55% in Cohort 1 but 90% in Cohort 2, the cohort that received a higher first dose and a reduced (fractional) fifth dose. Immune responses were better boosted by the fractional fifth dose in Cohort 2 and suggested the importance of the fractional fifth dose for increased protection in Cohort 2 responses. Three protected subjects were later boosted and were protected suggesting that protection could be extended to at least 67 weeks. Methods: The ex vivo FluoroSpot assay was used to measure peripheral IFN-γ, IL2, and IFN-γ+IL2 responses to PfNF54 sporozoites and malaria antigens CSP, AMA1, TRAP, and CelTOS using pools of synthetic overlapping 15mer peptides spanning each antigen. Results: There was no correlation between IFN-γ, IL2, and IFN-γ+IL2 responses to sporozoites and protection, but fold-increases between post-4th and post-5th responses greater than 1.0 occurred mostly in protected subjects. IFN-γ and IL2 responses to TRAP, CelTOS and CSP occurred only in protected subjects. Peripheral IFN-γ, IL2, and IFN-γ+IL2 responses were short-lived and low by 27 weeks post-CHMI but were restored by boosting. Conclusions: These studies highlight the importance of vaccine dose and schedule for vaccine efficacy, and suggest that CSP, TRAP, AMA1 and CelTOS may be targets of protective immunity. The correlation between fold-increases in responses and protection should be explored in other vaccine trials. Trial registration: ClinicalTrials.gov NCT01994525.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-08-20).
Identificativi: PMID 34415964 · PMCID PMC8378721 · DOI 10.1371/journal.pone.0256396.
Descrittori MeSH principali: Plasmodium falciparum; Sporozoites; Malaria, Falciparum; Protozoan Proteins; Malaria Vaccines.
Pagina: https://europepmc.org/article/MED/34415964 — https://doi.org/10.1371/journal.pone.0256396. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-03T06:07:59.323Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.